Breaking News

Par Pharma Appoints Commercial Officer

By Kristin Brooks | February 21, 2014

JHP’s Pera brings more than 30 years of industry experience

Antonio R. Pera has been named chief commercial officer at Par Pharmaceutical Companies. Mr. Pera will lead Par's newly-integrated sales and marketing organization following its acquisition of JHP Pharmaceuticals, and will manage relationships with its major trade partners.
 
Mr. Pera was previously with JHP, where he served as senior vice president, commercial operations. He has more than 30 years of experience in the pharma industry, including manufacturing and wholesale for generic and branded products. Prior to JHP, Mr. Pera was senior vice president, supply chain management at AmerisourceBergen Corp., where he served as a corporate officer and led the procurement function.
 
"Tony has enjoyed a distinguished career in the pharmaceutical industry and we are very pleased to have him join the Par team," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. "He has a demonstrated expertise in the marketing, sales and distribution of generic drugs. We look forward to the leadership Tony will provide our commercial organization and the many contributions he will make to our company."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important